Table 2

Effects of CEP-18770, bortezomib (BOR), high-dose dexamethasone (HD Dex), and melphalan (MLP) on survival in the systemic ARP-1 human multiple myeloma model

SurvivalVehicle groupCEP-18770 3 mg/kg intravenously once weeklyCEP-18770 3 mg/kg intravenously twice weeklyCEP-18770 4 mg/kg intravenously once weeklyCEP-18770 4 mg/kg intravenously twice weeklyBOR 1.2 mg/kg intravenously once weeklyBOR 1.2 mg/kg intravenously twice weeklyHD Dex 1.5 mg/kg intraperitoneally once dailyMLP 10 mg/kg intraperitoneally once daily
Mean, d 34.8 60.4 75.8 54.5 63.6 58.3 58.7 56.2 90.5 
Median, d 34 51 61.5 50 65 47 59 57 100 
SEM of median survival, d 5.5 10.5 13.7 10.4 11.3 11.2 6.7 5.7 9.3 
P values versus vehicle — .06 .02 .14 .05 .09 .02 .02 <.001 
SurvivalVehicle groupCEP-18770 3 mg/kg intravenously once weeklyCEP-18770 3 mg/kg intravenously twice weeklyCEP-18770 4 mg/kg intravenously once weeklyCEP-18770 4 mg/kg intravenously twice weeklyBOR 1.2 mg/kg intravenously once weeklyBOR 1.2 mg/kg intravenously twice weeklyHD Dex 1.5 mg/kg intraperitoneally once dailyMLP 10 mg/kg intraperitoneally once daily
Mean, d 34.8 60.4 75.8 54.5 63.6 58.3 58.7 56.2 90.5 
Median, d 34 51 61.5 50 65 47 59 57 100 
SEM of median survival, d 5.5 10.5 13.7 10.4 11.3 11.2 6.7 5.7 9.3 
P values versus vehicle — .06 .02 .14 .05 .09 .02 .02 <.001 

Survival data from Kaplan-Meier analyses of different dosing schedules of CEP-18770 and bortezomib relative to that achieved with first- line standard-of-care therapies used for the treatment of MM. Details and statistical analyses of data are described in “Systemic human multiple myeloma model.”

— indicates not applicable.

View Large